Olanzapin Pcd (Olanzapine)

Olanzapine, the active ingredient in Olanzapin Pcd, is a atypical antipsychotic presented as a tablet for oral use. It is primarily prescribed for the management of schizophrenia and bipolar disorder in adults.

GNH USA supplies Olanzapin Pcd as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olanzapine is indicated for several psychiatric conditions that involve dopamine and serotonin dysregulation.

- Schizophrenia: helps reduce hallucinations, delusions and thought disorder. - Bipolar I disorder (manic episodes): assists in controlling elevated mood, energy and activity levels. - Bipolar depression: contributes to improvement of depressive symptoms when used as part of a broader treatment plan. - Maintenance therapy: supports long‑term stability and relapse prevention in previously stabilized patients.

Olanzapine may cause a range of adverse reactions, from mild to potentially serious.

Common Side Effects: - Weight gain: increased appetite and caloric intake. - Sedation: drowsiness or feeling of being unusually tired. - Dry mouth: reduced salivation. - Constipation: infrequent or hard stools. - Elevated triglycerides: rise in blood lipid levels. - Orthostatic dizziness: light‑headedness when standing quickly.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: high fever, muscle rigidity, autonomic instability. - Tardive dyskinesia: involuntary, repetitive movements, often of the face. - Hyperglycaemia: significant rise in blood glucose, potentially leading to diabetes. - Seizures: occurrence of convulsive episodes. - Severe leukopenia: marked reduction in white‑blood cell count. - Cardiac arrhythmias: irregular heart rhythm, including QT prolongation.

When prescribing Olanzapine, clinicians should consider several safety aspects.

- Monitor: regular assessment of weight, fasting glucose, and lipid profile. - Caution: use in patients with a history of cardiovascular disease. - Avoid: co‑administration with strong CYP450 inhibitors that may raise plasma levels. - Adjust: dose may need modification in hepatic or renal impairment. - Educate: patients should be advised   - Store at ambient temperature: keep in original packaging  

The pharmacokinetic profile of  

Major  

-  

Moderate 

  g